Publications by authors named "Alienor Berges"

Claim this Profile
A
A Combined Model-Based Meta-Analysis of Aggregated and Individual FEV1 Data From Randomized COPD Trials.
Liang Yang, Carolina Llanos-Paez, Shuying Yang, Claire Ambery, Alienor Berges

CPT Pharmacometrics Syst Pharmacol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis.
Anders Thorsted, Chiara Zecchin, Alienor Berges, Mats O Karlsson, Lena E Friberg

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance.
Gael Cantet, Alienor Berges, Rhianna O'Sullivan, Sarit Cohen-Rabbie, Corina Dota

Br J Clin Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Alienor Berges

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Seung Tae Kim, Simon A Smith, Peter Mortimer, Arsene-Bienvenu Loembé, Heejin Cho, Alienor Berges

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019.
Sarit Cohen-Rabbie, Alienor C Berges, Dinko Rekić, Joanna Parkinson, Corina Dota

J Clin Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.
Armin Sepp, Guy Meno-Tetang, Andrew Weber, Andrew Sanderson, Oliver Schon, Alienor Berges

J Pharmacokinet Pharmacodyn· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.
Gopichand Gottipati, Alienor C Berges, Shuying Yang, Chao Chen, Mats O Karlsson

Pharm Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Alienor Berges

Clin Pharmacol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Alienor Berges

Clin Pharmacokinet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology.
Alienor Berges, Marc Cerou, Tarjinder Sahota, Lia Liefaard, Claire Ambery

Toxicol Sci· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies.
Alienor Berges, Jonathan Bullman, Stewart Bates, David Krull, Nicola Williams

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug development.
Anaïs Glatard, Aliénor Berges, Tarjinder Sahota, Claire Ambery, Jan Osborne

Toxicol Appl Pharmacol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
Duncan B Richards, Louise M Cookson, Alienor C Berges, Sharon V Barton, Thirusha Lane

N Engl J Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory.
Armin Sepp, Alienor Berges, Andrew Sanderson, Guy Meno-Tetang

J Pharmacokinet Pharmacodyn· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Vincent Meininger, Pierre-François Pradat, Andrea Corse, Safa Al-Sarraj, Benjamin Rix Brooks, Alienor Berges

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Richard A Grove, Conn M Harrington, Andreas Mahler, Isabel Beresford, Paul Maruff, Alienor C Berges

Curr Alzheimer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders.
R Norman Harden, Roy Freeman, Michelle Rainka, Lixin Zhang, Chris Bell, Alienor Berges

Pain Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non linear mixed effects analysis in PET PK-receptor occupancy studies.
Alienor Berges, Vincent J Cunningham, Roger N Gunn, Stefano Zamuner

Neuroimage· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose finding by concentration-response versus dose-response: a simulation-based comparison.
Alienor Berges, Chao Chen

Eur J Clin Pharmacol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation.
Pradeep J Nathan, Rebecca Boardley, Nicola Scott, Alienor Berges, Paul Maruff

Curr Alzheimer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers.
Alienor Berges, Jonathan Robertson, James Upward, Scott Meyers, Chao Chen

Clin Pharmacol Drug Dev· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
Alienor Berges, Christine Walls, Shelly E Lener, Susan A McDonald

Clin Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis